Experimental HIV vaccine passes early safety test in healthy volunteers

NCT ID NCT03220724

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental HIV vaccine in 117 healthy, HIV-negative adults to see if it is safe and triggers an immune response. Participants received several injections of the vaccine or a placebo. The main goals were to check for side effects and measure antibody levels. Results will guide future HIV vaccine research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Experimental HIV vaccine (EnvSeq-1 and CH505 M5 gp120 proteins with GLA-SE adjuvant)
What this could lead to: If successful, this could help develop a vaccine to prevent HIV infection.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The vaccine may not produce strong enough immunity to prevent HIV, and further studies are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Alabama CRS

Birmingham, Alabama, 35294, United States
Bridge HIV CRS

San Francisco, California, 94102, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

Boston, Massachusetts, 02115-6110, United States
Columbia P&S CRS

New York, New York, 10032-3732, United States
New York Blood Center CRS

New York, New York, 10065, United States
Penn Prevention CRS

Philadelphia, Pennsylvania, 19104, United States
Seattle Vaccine and Prevention CRS

Seattle, Washington, 98104, United States
University of Rochester Vaccines to Prevent HIV Infection CRS

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.